Genomics in breast cancer—therapeutic implications
- 1 January 2005
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Clinical Practice Oncology
- Vol. 2 (1), 26-33
- https://doi.org/10.1038/ncponc0072
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Study of suboptimum treatment response: lessons from breast cancerThe Lancet Oncology, 2003
- Options available—from start to finish—for obtaining data from DNA microarrays IINature Genetics, 2002
- Standards for Microarray DataScience, 2002
- The fall in breast cancer mortality in EuropeEuropean Journal of Cancer, 2001
- Computational analysis of microarray dataNature Reviews Genetics, 2001
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast CancerThe New England Journal of Medicine, 1994